These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1330402)

  • 1. Decreased faecal exoglycosidase activities identify a subset of patients with active Crohn's disease.
    el Yamani J; Mizon C; Capon C; Colombel JF; Fournet B; Cortot A; Mizon J
    Clin Sci (Lond); 1992 Oct; 83(4):409-15. PubMed ID: 1330402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease.
    Rhodes JM; Gallimore R; Elias E; Allan RN; Kennedy JF
    Gut; 1985 Aug; 26(8):761-5. PubMed ID: 2991089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deglycosylation of alpha 1-proteinase inhibitor is impaired in the faeces of patients with active inflammatory bowel disease (Crohn's disease).
    Mizon C; el Yamani J; Colombel JF; Maes P; Balduyck M; Laine A; Cortot A; Tartar A; Mizon J
    Clin Sci (Lond); 1991 May; 80(5):517-23. PubMed ID: 1851694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple method for the measurement of different forms of alpha 1 proteinase inhibitor in the faeces of patients with Crohn's disease.
    el Yamani J; Soudan B; Mizon C; Colombel JF; Balduyck M; Cortot A; Mizon J
    Ann Clin Biochem; 1992 Jul; 29 ( Pt 4)():418-21. PubMed ID: 1642448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease.
    Colombel JF; Mizon C; Balduyck M; Cortot A
    Gut; 1989 Feb; 30(2):279-80. PubMed ID: 2784776
    [No Abstract]   [Full Text] [Related]  

  • 6. Structural heterogeneity of faecal alpha 1 antitrypsin shown by immunoblot analysis in patients with Crohn's disease.
    Boege F; Fischbach W
    Gut; 1991 May; 32(5):496-9. PubMed ID: 2040471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased faecal glycosidases in patients with Crohn's disease.
    Ruseler-van Embden JG; van Lieshout LM
    Digestion; 1987; 37(1):43-50. PubMed ID: 3609504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease.
    Carrette O; Favier C; Mizon C; Neut C; Cortot A; Colombel JF; Mizon J
    Dig Dis Sci; 1995 Dec; 40(12):2641-6. PubMed ID: 8536525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease.
    Favier C; Neut C; Mizon C; Cortot A; Colombel JF; Mizon J
    Dig Dis Sci; 1997 Apr; 42(4):817-22. PubMed ID: 9125655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal alpha 1-antitrypsin measurement: an indicator of Crohn's disease activity.
    Meyers S; Wolke A; Field SP; Feuer EJ; Johnson JW; Janowitz HD
    Gastroenterology; 1985 Jul; 89(1):13-8. PubMed ID: 3874110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal elastase reflects disease activity in active ulcerative colitis.
    Adeyemi EO; Hodgson HJ
    Scand J Gastroenterol; 1992; 27(2):139-42. PubMed ID: 1561528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decrease of fecal beta-galactosidase activity in Crohn disease].
    Canva-Delcambre V; Soenen V; Mizon C; Cortot A; Mizon J; Colombel JF
    Gastroenterol Clin Biol; 1993; 17(10):718-22. PubMed ID: 8288080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased proteolysis and leucine aminopeptidase activity in faeces of patients with Crohn's disease.
    Ruseler-van Embden JG; van Lieshout LM
    Digestion; 1988; 40(1):33-40. PubMed ID: 3069527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Cellier C; Sahmoud T; Froguel E; Adenis A; Belaiche J; Bretagne JF; Florent C; Bouvry M; Mary JY; Modigliani R
    Gut; 1994 Feb; 35(2):231-5. PubMed ID: 7508411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease.
    Mizon C; Becuwe C; Balduyck M; Colombel JF; Cortot A; Mizon J; Degand P
    Clin Chem; 1988 Nov; 34(11):2268-70. PubMed ID: 3263222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain glycosidases in Creutzfeldt-Jakob disease.
    Annunziata P; Federico A
    J Neurol Sci; 1981 Feb; 49(2):325-8. PubMed ID: 6783737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy].
    Colombel JF; Mizon C; Chekkouri N; Balduyck M; Chaussade S; Becuwe C; Degand P; Mizon J; Cortot A
    Gastroenterol Clin Biol; 1991; 15(4):301-5. PubMed ID: 2060740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fecal excretion and the clearance of alpha 1-antitrypsin in patients with Crohn's disease].
    López A; Hinojosa J; Miralles A; Primo J; Bermúdez JD
    Rev Esp Enferm Dig; 1993 Apr; 83(4):235-9. PubMed ID: 8494651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of glycosidases in human colonic adenocarcinoma.
    Gil-Martín E; Rodríguez-Berrocal J; Páez de la Cadena M; Fernández-Briera A
    Clin Biochem; 1997 Feb; 30(1):17-25. PubMed ID: 9056105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal sulphatase in health and in inflammatory bowel disease.
    Rhodes JM; Gallimore R; Elias E; Kennedy JF
    Gut; 1985 May; 26(5):466-9. PubMed ID: 3996936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.